These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 18248643

  • 1. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 2. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B, Radzikowska M, Wasilewska-Dziubińska E, Kapliński A, Roguski K, Płonowski A.
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [Abstract] [Full Text] [Related]

  • 3. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
    Guido M, Romualdi D, De Marinis L, Porcelli T, Giuliani M, Costantini B, Lanzone A.
    Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
    [Abstract] [Full Text] [Related]

  • 4. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 5. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome.
    Zwirska-Korczala K, Sodowski K, Konturek SJ, Kuka D, Kukla M, Brzozowski T, Cnota W, Woźniak-Grygiel E, Jaworek J, Bułdak R, Rybus-Kalinowska B, Fryczowski M.
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():161-78. PubMed ID: 18812636
    [Abstract] [Full Text] [Related]

  • 6. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V, Nagamani M.
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [Abstract] [Full Text] [Related]

  • 7. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Serum levels of ghrelin and leptin in women with polycystic ovary syndrome].
    Pekhlivanov B, Mitkov M, Orbtsova M, Terzieva D.
    Akush Ginekol (Sofiia); 2008 Jan; 47(3):15-9. PubMed ID: 18756827
    [Abstract] [Full Text] [Related]

  • 10. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z.
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [Abstract] [Full Text] [Related]

  • 11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuçcu R.
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec 01; 123(2):204-11. PubMed ID: 16316811
    [Abstract] [Full Text] [Related]

  • 13. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D.
    Clin Endocrinol (Oxf); 2007 Jan 01; 66(1):103-9. PubMed ID: 17201808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF.
    Diabetes Care; 2007 Sep 01; 30(9):2309-13. PubMed ID: 17536071
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hormonal levels of leptin, insulin, ghrelin, and neuropeptide Y in lean, overweight, and obese Saudi females.
    Daghestani MH, Ozand PT, Al-Himadi AR, Al-Odaib AN.
    Saudi Med J; 2007 Aug 01; 28(8):1191-7. PubMed ID: 17676200
    [Abstract] [Full Text] [Related]

  • 19. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
    Romualdi D, Costantini B, Campagna G, Lanzone A, Guido M.
    Fertil Steril; 2008 Nov 01; 90(5):1826-33. PubMed ID: 18166189
    [Abstract] [Full Text] [Related]

  • 20. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM.
    Gynecol Endocrinol; 2007 Mar 01; 23(3):146-52. PubMed ID: 17454168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.